Clinical trials
Age-Related Macular Degeneration clinical trials
Below are recruiting age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05675150Recruiting
Art-based program for adults with age-related vision loss
This trial tests whether an expressive arts-based program can help adults who have age-related macular degeneration (a common cause of vision loss) by supporting wellbeing and daily functioning. If you meet the language, vision, and health requirements, participating may help you benefit from a structured arts intervention.
Hong KongAges 50–80 - NCT05803785RecruitingPhase 1
Safety study of an injection for wet macular degeneration
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Sydney, New South WalesAges 50 years+ - NCT05913063Recruiting
Testing how the eye responds to tiny quantum states
This study looks at how the human eye detects very small “quantum” information. It compares people with certain vision conditions to people with normal vision to see how the eye’s macula and overall vision are involved.
Hong Kong, GuangdongAges 18 years+ - NCT05959005Recruiting
Tracking early macular atrophy changes in the eye
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Salt Lake City, UtahAges 50 years+ - NCT06046118Recruiting
Light therapy for dry age-related macular degeneration
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
ParisAges 50 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Manchester, ConnecticutAges 50 years+ - NCT06271330Recruiting
Switching older injections to faricimab for wet AMD
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Nantes, NantesAges 18 years+ - NCT06319872RecruitingPhase 1
Study of disulfiram for vision in retinal degeneration
This trial tests whether disulfiram, a drug used for alcohol use disorder, can improve vision in people with retinal degeneration. You must have an alcohol use diagnosis and agree to avoid alcohol for 6 months.
Rochester, New YorkAges 18 years+ - NCT06346600Recruiting
Long-term follow-up for SKG0106 in wet AMD
This study follows people who already received the SKG0106 injection in a previous trial for wet age-related macular degeneration (nAMD). It checks how they are doing over a longer period.
Boston, MassachusettsAges 50 years+ - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT06355830Recruiting
A study of intermediate age-related macular degeneration
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
LisbonAges 55–95 - NCT06375239Recruiting
Study of tests for tracking vision in retinal disease
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
Irvine, CaliforniaAges 18 years+ - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT06458595RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration (nAMD)
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
TianjinAges 50–85 - NCT06489873Recruiting
Lutein, Zeaxanthin, and Fish Oil for Macular Health
This study tests whether taking daily supplements of lutein, zeaxanthin, and fish oil can improve the protective pigment in your eyes. It may help people with low macular pigment and good vision who are not already taking high doses of these nutrients.
College Station, TexasAges 18–45 - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Beverly Hills, CaliforniaAges 55–90 - NCT06593405RecruitingEarly Phase 1
Occupational therapy for eye disease medication management
This trial tests whether occupational therapy can help people with age-related macular degeneration (AMD), diabetic retinopathy (DR), or glaucoma better manage their medications. Participants share their deidentified data to see if therapy improves outcomes.
Worcester, MassachusettsAges 50–100 - NCT03848663Recruiting
Training with visual remapping to help reading with central vision loss
This study tests whether a computer-based visual training method (“remapping”) can help people read better even when they have reduced central vision. You may benefit if your eye condition is stable and your eyes can reliably track the training on an eye-tracker.
Minneapolis, MinnesotaAges 16 years+ - NCT06604104Recruiting
Visual Frailty Study in Older Adults with AMD
This study looks at something called 'visual frailty' in older adults with advanced age-related macular degeneration (AMD). It aims to develop a tool to better understand how vision loss affects daily life and overall health in people aged 60 and over.
Edinburgh, ScotlandAges 60 years+ - NCT06635148RecruitingPhase 2
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Tucson, ArizonaAges 60 years+ - NCT06694272Recruiting
Visual function tests for early age-related macular degeneration
This study looks at how well the eyes function in people with early or intermediate age-related macular degeneration (AMD). It uses imaging and vision tests to help doctors better understand the condition.
ParisAges 18 years+ - NCT07587515RecruitingPhase 1/Phase 2
New Eye Drop Treatment for Wet Age-Related Macular Degeneration
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Beverly Hills, CaliforniaAges 50 years+ - NCT06843499Recruiting
AI eye screening for AMD and diabetic retinopathy
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
Taipei, TaiwanAges 20 years+
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for age-related macular degeneration?
- Yes. Clin2 currently lists 138 recruiting age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.